BESTOW: A Phase 2, Multicenter, Randomized, Open-Label Study to Evaluate the Safety and Efficacy of Tegoprubart in Patients Undergoing Kidney Transplantation

Status: Recruiting

Eligibility Criteria

Sex: Male or Female
Age Group: 18 years and over
This study is NOT accepting healthy volunteers

Inclusion Criteria:

- 18 to 100 years old - recipient of first kidney transplant from a living or deceased donor - agree to comply with contraception requirements during and for at least 90 days after the last administration of study drug

Exclusion Criteria:

- previously received a bone marrow transplant or any other solid organ transplant, including a kidney, or will be undergoing a multi organ or dual kidney transplant - medical conditions that require chronic use of systemic steroids at a dose higher than 5 mg prednisone or equivalent per day - additional criteria apply (study staff will review)

Conditions & Interventions

Interventions:
Drug: AT-1501
Conditions:
Kidney, Prostate & Urinary
Keywords:
kidney transplant

More Information

Description: The purpose of this study is to test whether the investigational drug, tegoprubart, in combination with the same standard immunosuppressive medicines (anti-thymocyte globulin, corticosteroids, and mycophenolate) is safe, tolerable and effective compared to tacrolimus. The study will specifically look at the function of the implanted kidney in the tegoprubart group compared to the tacrolimus group and will also assess how well tegoprubart prevents diabetes and prevents rejection.
Study Contact: Kristin Mathson - maths022@umn.edu
Principal Investigator: Andrew Adams
IRB Number: SITE00001922